Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly and Company has granted an additional funding of over $4m to Infectious Disease Research Institute (IDRI), over the upcoming four and a half years, for early phase drug discovery research.
Subscribe to our email newsletter
IDRI research lays emphasis on identifying new therapies to fight tuberculosis (TB), including multidrug-resistant TB (MDR-TB).
The additional funding through Eli Lilly to support early stage TB drug discovery efforts through IDRI brings the total amount to $20m.
Eli Lilly and Company senior research fellow Philip Hipskind said they have made strong links with IDRI and intend to bolster the drug discovery capabilities of each organization.